EGPAF, with funding and support from Unitaid and DNDi, is bringing new-to-market pediatric ARV formulations to full-scale implementation in eight African countries. We gathered and documented lessons learned from these eight project countries to inform, streamline and accelerate the introduction and roll-out of new, child-friendly ARVs so that all children living with HIV have access to optimal, WHO-recommended treatment and care.
Explore Related Resources
February 2022, HEALTH CENTER OF MACIA, Locality Macia, District of Xai Xai, Gaza Province, Mozambique. Delivering a ARVs Bottle in a private pharmacy.
Journal Articles
HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique
Published January 2025
Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021–February 2022), including adults on first-line ART for ≥12 months […]
View Resource
Topics:
HIV
Countries:
Mozambique
Journal Articles
Clients’ and providers’ perspectives in informing a digital health intervention to improve linkage to care after Index HIV self-testing in Hai and Moshi Districts, Tanzania
Published November 2024
Background Digital health interventions have the potential to improve linkage to care after HIV self-testing (HIVST). This study aimed to understand clients’ and providers’ perceptions of benefits, and barriers of a digital health intervention designed to improve linkage to care after HIV self-testing in Tanzania. Methods This exploratory qualitative research study was conducted in Hai […]
View Resource
Topics:
HIV
Countries:
Tanzania
Adolescents join for a field day at Lobamba clinic in Eswatini
Journal Articles
Follow-Up Outcomes of Children, Adolescents, and Young People on Darunavir-Based Third-Line Antiretroviral Therapy
Published October 2024
Background: We assessed clinical outcomes among children, adolescents, and people younger than 25 years on darunavir-based antiretroviral therapy (ART) in 9 sub-Saharan African countries. Setting: Third-line ART centers in Cameroon, Eswatini, Kenya, Lesotho, Nigeria, Rwanda, Uganda, Zambia, and Zimbabwe. Methods: From January 2019 to December 2022, we collected data from a cohort of children, adolescents, and young people […]
View Resource
Topics:
Adolescents,
Pediatric HIV
Countries:
Cameroon,
Eswatini,
Kenya,
Lesotho,
Nigeria,
Rwanda,
Uganda,
Zambia,
Zimbabwe